Approval · Notice of Compliance 20055 · 2017
VICTOZA: Notice of Compliance 20055
Issued November 17, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20055
- Date
- November 17, 2017
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication and updates to the product monograph: add-on combination in patients with established cardiovascular disease: victoza is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VICTOZA | Not yet assigned | — |
Medicinal ingredients
- LIRAGLUTIDE 6 MG per ML